StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Equities researchers at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report released on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.

A number of other analysts also recently weighed in on CLLS. Oppenheimer reduced their price target on shares of Cellectis from $11.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, June 12th. JMP Securities reiterated a “market outperform” rating and issued a $6.00 target price on shares of Cellectis in a research note on Friday, May 31st.

Cellectis Trading Down 3.8 %

Cellectis stock opened at $1.89 on Friday. The business’s 50-day simple moving average is $2.67 and its 200-day simple moving average is $2.79. Cellectis has a 52 week low of $0.96 and a 52 week high of $3.77. The firm has a market capitalization of $105.05 million, a PE ratio of -1.47 and a beta of 3.09. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.63 and a current ratio of 1.63.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) EPS for the quarter. Cellectis had a negative return on equity of 67.41% and a negative net margin of 529.81%. The business had revenue of $6.50 million for the quarter. Equities research analysts forecast that Cellectis will post -0.54 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

A hedge fund recently raised its stake in Cellectis stock. Baillie Gifford & Co. lifted its holdings in shares of Cellectis S.A. (NASDAQ:CLLS) by 1.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 827,248 shares of the biotechnology company’s stock after acquiring an additional 10,605 shares during the period. Baillie Gifford & Co. owned approximately 1.49% of Cellectis worth $2,192,000 as of its most recent filing with the SEC. 63.90% of the stock is owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.